EA202190266A1 - Рекомбинантные захватывающие белки клеточной поверхности - Google Patents

Рекомбинантные захватывающие белки клеточной поверхности

Info

Publication number
EA202190266A1
EA202190266A1 EA202190266A EA202190266A EA202190266A1 EA 202190266 A1 EA202190266 A1 EA 202190266A1 EA 202190266 A EA202190266 A EA 202190266A EA 202190266 A EA202190266 A EA 202190266A EA 202190266 A1 EA202190266 A1 EA 202190266A1
Authority
EA
Eurasian Patent Office
Prior art keywords
domain
cell surface
capture proteins
proteins
interest
Prior art date
Application number
EA202190266A
Other languages
English (en)
Inventor
Дипали Дешпанде
Ган Чэнь
Дарья Бураков
Джеймс Фэнлд
Томас Олдрич
Вишал Камат
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Publication of EA202190266A1 publication Critical patent/EA202190266A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

Обеспечиваются рекомбинантные захватывающие белки клеточной поверхности и детекторные молекулы, которые применимы для выделения и детектирования клеток, которые продуцируют секретируемый гетеродимерный белок, представляющий интерес (POI), который содержит CH3-домен иммуноглобулина и/или замещенный CH3-домен. Также обеспечиваются рекомбинантные захватывающие белки клеточной поверхности и детекторные молекулы, которые позволяют выделить и детектировать биспецифические антитела. Настоящим изобретением также обеспечиваются рекомбинантные антигенсвязывающие белки, которые способны распознавать и связывать представляющие интерес белки, которые содержат CH3-домен и/или модифицированный CH3-домен, такой как CH3-домен с аминокислотными заменами в H95 и Y96 (IMGT) или без них.
EA202190266A 2012-11-14 2013-11-14 Рекомбинантные захватывающие белки клеточной поверхности EA202190266A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261726040P 2012-11-14 2012-11-14

Publications (1)

Publication Number Publication Date
EA202190266A1 true EA202190266A1 (ru) 2021-07-30

Family

ID=49679651

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201590928A EA037546B1 (ru) 2012-11-14 2013-11-14 Рекомбинантные захватывающие белки клеточной поверхности
EA202190266A EA202190266A1 (ru) 2012-11-14 2013-11-14 Рекомбинантные захватывающие белки клеточной поверхности

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201590928A EA037546B1 (ru) 2012-11-14 2013-11-14 Рекомбинантные захватывающие белки клеточной поверхности

Country Status (20)

Country Link
US (3) US9758592B2 (ru)
EP (2) EP2920208B1 (ru)
JP (2) JP6668074B2 (ru)
KR (4) KR20210014766A (ru)
CN (2) CN104797598B (ru)
AR (2) AR093491A1 (ru)
AU (3) AU2013344769B2 (ru)
BR (1) BR112015010758A2 (ru)
CA (2) CA3204343A1 (ru)
DK (2) DK2949667T3 (ru)
EA (2) EA037546B1 (ru)
ES (2) ES2817373T3 (ru)
HK (2) HK1211036A1 (ru)
IL (3) IL238176B (ru)
MX (2) MX2015006112A (ru)
PL (2) PL2949667T3 (ru)
SG (2) SG10201804124XA (ru)
TW (3) TWI745610B (ru)
WO (1) WO2014078475A2 (ru)
ZA (1) ZA201502538B (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
WO2011159847A2 (en) 2010-06-15 2011-12-22 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof
US9217040B2 (en) 2011-01-14 2015-12-22 The Regents Of The University Of California Therapeutic antibodies against ROR-1 protein and methods for use of same
CN104662044B (zh) 2012-08-24 2018-10-30 加利福尼亚大学董事会 用于治疗ror1癌症并抑制转移的抗体和疫苗
TWI745610B (zh) 2012-11-14 2021-11-11 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
EA038931B9 (ru) * 2014-11-20 2022-02-18 Йиссум Рисерч Дивелопмент Компани Оф Зе Хебрю Юниверсити Оф Иерусалим Лтд. Композиции и способы получения полипептидов с модифицированным профилем гликозилирования в клетках растений
MA56416A (fr) 2015-05-12 2022-05-04 Regeneron Pharma Détermination de la pureté de protéines multimériques
JP7020687B2 (ja) 2015-09-15 2022-02-16 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｔ細胞受容体（ｔｃｒ）結合抗体及びその使用
JP7096770B2 (ja) 2016-04-20 2022-07-06 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 発現強化座位の使用に基づいた抗体を作製するための組成物および方法
BR112018071285A2 (pt) 2016-04-20 2019-02-12 Regeneron Pharma célula, conjunto de vetores, vetor, sistema, e, método
MX2018016330A (es) 2016-06-27 2020-02-17 Univ California Combinaciones para tratamiento del cáncer.
EP3601558A4 (en) * 2017-03-24 2021-01-06 Lankenau Institute for Medical Research METHODS AND COMPOSITIONS FOR CAPTURE OF INDUCTIBLE EXTRACELLULAR MEMBRANE OF MONOCLONAL IMMUNOGLOBULINS SECRETED BY HYBRIDOMAS
CN107177613A (zh) * 2017-07-18 2017-09-19 哈尔滨紫霞生物科技有限公司 一种提高重组猪干扰素‑γ融合蛋白抗病毒活性的方法
JP7425725B2 (ja) * 2017-12-07 2024-01-31 中外製薬株式会社 試料中のポリペプチドの検出または捕捉において使用するための抗体、組成物、および試料中のポリペプチドの検出または捕捉のための方法
US20220033845A1 (en) * 2018-09-24 2022-02-03 Merck Sharp & Dohme Corp. Expression vectors for eukaryotic expression systems
US20220144916A1 (en) * 2019-02-12 2022-05-12 Board Of Regents, The University Of Texas System High affinity engineered t-cell receptors targeting cmv infected cells
CN114874333A (zh) * 2021-10-18 2022-08-09 深圳科兴药业有限公司 一种生长激素融合蛋白及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5151350A (en) * 1982-10-27 1992-09-29 Repligen Corporation Cloned genes encoding recombinant protein a
US5635354A (en) 1991-01-09 1997-06-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for describing the repertoires of antibodies (Ab) and of T-cell receptors (TcR) of an individual's immune system
US6399368B1 (en) 1992-01-17 2002-06-04 Board Of Regents, The University Of Texas System Secretion of T cell receptor fragments from recombinant Escherichia coli cells
US6080840A (en) 1992-01-17 2000-06-27 Slanetz; Alfred E. Soluble T cell receptors
CA2146974C (en) 1992-10-21 2010-02-02 Andreas Radbruch Direct selection of cells by secretion product
US6482655B1 (en) 1993-07-23 2002-11-19 University Of Utah Research Foundation Immunoassay procedure utilizing fluorogenic tracer antigens
US6287784B1 (en) 1993-11-23 2001-09-11 Genentech, Inc. Kinase receptor activation assay
US6410690B1 (en) * 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
HU228630B1 (en) 1996-02-09 2013-04-29 Abbott Biotech Ltd Use of human anti bodies that bind human tnf-alpha and process for inhibiting of human tnf-alpha activity
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6232066B1 (en) 1997-12-19 2001-05-15 Neogen, Inc. High throughput assay system
JP4601166B2 (ja) 1998-05-11 2010-12-22 ミルテニィ バイオテック ゲーエムベーハー 抗原特異的ｔ細胞の直接的選択方法
JP3471006B2 (ja) 1998-05-20 2003-11-25 中外製薬株式会社 新規な遺伝子クローニング方法
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
DE19900635A1 (de) 1999-01-11 2000-07-13 Deutsches Krebsforsch Selektion von monoklonalen Antikörpern
US7138496B2 (en) 2002-02-08 2006-11-21 Genetastix Corporation Human monoclonal antibodies against human CXCR4
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20140072979A1 (en) 2001-01-16 2014-03-13 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
US20140072980A1 (en) 2001-01-16 2014-03-13 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
AU2002245272B2 (en) 2001-01-16 2006-06-29 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
KR100899970B1 (ko) 2001-02-19 2009-05-28 메르크 파텐트 게엠베하 Ｔ-세포 에피토프의 동정 방법 및 감소된 면역원성을 갖는분자의 제조를 위한 용도
ATE290020T1 (de) 2001-08-31 2005-03-15 Avidex Ltd Löslicher t zell rezeptor
EP2093286B1 (en) 2001-10-01 2013-02-27 Dyax Corporation Multi-chain eukaryotic display vectors and uses thereof
EP1888649A2 (en) * 2005-05-09 2008-02-20 GlycArt Biotechnology AG Antigen binding molecules having modified fc regions and altered binding to fc receptors
ME00973B (me) * 2007-07-31 2012-06-20 Regeneron Pharma Humana antitjela prema humanom cd20 i postupak njihovog korišćenja
US20090162359A1 (en) * 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
EP2445936A1 (en) * 2009-06-26 2012-05-02 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
MX2012007497A (es) * 2009-12-25 2012-08-01 Chugai Pharmaceutical Co Ltd Metodo para modificacion de polipeptidos para purificar multimeros de polipeptido.
TWI745610B (zh) 2012-11-14 2021-11-11 美商再生元醫藥公司 重組細胞表面捕捉蛋白質

Also Published As

Publication number Publication date
IL238176A0 (en) 2015-05-31
KR20150084028A (ko) 2015-07-21
KR20230119245A (ko) 2023-08-16
CA3204343A1 (en) 2014-05-22
AR121002A2 (es) 2022-04-06
JP6668074B2 (ja) 2020-03-18
IL285015A (en) 2021-08-31
EP2949667A2 (en) 2015-12-02
KR20210014766A (ko) 2021-02-09
TW201439121A (zh) 2014-10-16
AU2021202371A1 (en) 2021-05-13
US20180118852A1 (en) 2018-05-03
US9758592B2 (en) 2017-09-12
CN104797598A (zh) 2015-07-22
TWI675044B (zh) 2019-10-21
PL2949667T3 (pl) 2020-11-16
IL275270B (en) 2021-08-31
SG10201804124XA (en) 2018-07-30
AU2018253474A1 (en) 2018-11-15
CN104797598B (zh) 2018-12-11
BR112015010758A2 (pt) 2017-08-22
TW202206465A (zh) 2022-02-16
WO2014078475A2 (en) 2014-05-22
DK2920208T3 (da) 2020-09-14
EP2920208B1 (en) 2020-08-19
HK1211036A1 (en) 2016-05-13
WO2014078475A3 (en) 2014-11-20
CA2889541A1 (en) 2014-05-22
AU2013344769B2 (en) 2018-11-15
ES2817373T3 (es) 2021-04-07
KR20220025902A (ko) 2022-03-03
EP2920208A2 (en) 2015-09-23
EP2949667A3 (en) 2016-02-24
AU2018253474B2 (en) 2021-01-21
EP2949667B1 (en) 2020-05-13
AR093491A1 (es) 2015-06-10
JP6856593B2 (ja) 2021-04-07
CN109485728A (zh) 2019-03-19
CA2889541C (en) 2023-07-04
PL2920208T3 (pl) 2021-02-08
IL238176B (en) 2020-06-30
US20210009714A1 (en) 2021-01-14
MX2015006112A (es) 2015-08-06
AU2013344769A1 (en) 2015-05-21
SG11201502629TA (en) 2015-05-28
MX2019015887A (es) 2020-02-07
ZA201502538B (en) 2017-09-27
TWI745610B (zh) 2021-11-11
KR102563030B1 (ko) 2023-08-03
HK1214612A1 (zh) 2016-07-29
DK2949667T3 (da) 2020-07-20
EA201590928A1 (ru) 2015-09-30
JP2019023199A (ja) 2019-02-14
EA037546B1 (ru) 2021-04-12
US20140134719A1 (en) 2014-05-15
TW201920289A (zh) 2019-06-01
ES2805526T3 (es) 2021-02-12
JP2015536345A (ja) 2015-12-21
IL275270A (en) 2020-07-30

Similar Documents

Publication Publication Date Title
EA202190266A1 (ru) Рекомбинантные захватывающие белки клеточной поверхности
CY1123518T1 (el) Ανθρωπινα αντισωματα enanti-tau
CY1120951T1 (el) Ανθρωπινα αντισωματα enanti-tau
EA201591407A1 (ru) Антитела, содержащие химерные константные домены
EA201591091A1 (ru) Антигенсвязывающие белки для bcma
WO2015038884A3 (en) Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products
MA38632A1 (fr) Anticorps anti-récepteur de transferrine et procédés d'utilisation
WO2014200910A3 (en) Bioinformatic processes for determination of peptide binding
WO2014165082A3 (en) Antibodies and methods of detection
AR093984A1 (es) Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
CO6280541A2 (es) Anticuerpos monoclonales o fragmentos del mismo que se unen al recptor humano ox40
EA201400488A1 (ru) Полипептидные конструкции и их применение
IN2015DN00091A (ru)
EA201490825A1 (ru) Tdp-43-специфически связывающие молекулы
BR112017006598A2 (pt) anticorpo de repetições antidipeptídeo derivado de ser humano (dprs)
WO2013040142A3 (en) Bioinformatic processes for determination of peptide binding
WO2013078455A3 (en) Proteomic identification of antibodies
EP2534257A4 (en) METHOD OF IDENTIFYING AND ISOLATING CELLS FOR THE EXPRESSION OF POLYPEPTIDES
IN2014CN02113A (ru)
MX336109B (es) Formacion de imagenes inmuno-tep de anticuerpos e inmunoconjugados y usos de lo mismo.
MX353464B (es) Antigenos tpn47 de treponema pallidum, inmunoreactivos, solubles.
WO2015112558A3 (en) Peptides, devices, and methods for the detection of anaplasma antibodies
WO2011050985A8 (en) Clonal expansion of b cells
WO2013167727A3 (en) Method for determining arthritis relapse risk
WO2011137389A3 (en) Compositions and methods for reliably detecting and/or measuring the amount of a modified target protein in a sample